Clinical Trial Update: Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting participant-reported outcomes for trifarotene 50 μg/g cream in moderate facial and truncal acne vulgaris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• trifarotene 50 μg/g cream (trifarotene)

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2021-12-15